ZYDUSLIFE - Zydus Lifesciences Limited Share Price

In the Q3 FY26 earnings call, Zydus Lifesciences' management provided a favorable outlook, emphasizing strong double-digit growth and operational profitability. Key performance highlights included consolidated revenues of Rs.68.6 billion, reflecting a 30% year-on-year increase. EBITDA was reported at Rs.18.2 billion, up 31% year-on-year, with an EBITDA margin of 26.5%.

Significant forward-looking points from management include:

1. US Market Growth: The North America business achieved revenues of Rs.28 billion, up 16% year-on-year, supported by 18 ANDA filings and 8 approvals. Management is optimistic about the upcoming NDA filing for their specialty molecule Saroglitazar in the US, expected to catalyze growth.

2. Innovation and R&D Focus: Zydus is expanding its portfolio in rare diseases, launching Zycubo as the first treatment for Menkes disease. Future R&D commitments aim for 7.5%-8% of revenues, targeting multiple clinical trials and expanding biosimilar developments.

3. Consumer Wellness Expansion: The Consumer Wellness segment reported revenues of Rs.9.6 billion, a 113% increase driven by the Comfort Click acquisition. Plans to broaden this portfolio with new products are in motion.

4. International Formulations Growth: The company is witnessing robust growth in international markets, projecting double-digit growth, particularly in emerging markets and Europe, driven by localized offerings.

5. MedTech Advances: Approval of the Andy robotic surgical system marks a significant milestone in their MedTech endeavors.

Management also indicated that they expect 20%+ growth in international markets and a stable margin of 23% despite pressures from acquisitions and R&D expenditures. They acknowledged future costs associated with their Saro product commercialization and ongoing biosimilar developments.

Question 1: "Now that we have completed the acquisition of the asset, when should we start assuming revenue from the CDMO business? Would it be FY27, the latter half, FY28, or could it take some more time?"

Answer: "You'll see the commercialization start from the second half of FY27 when we begin supplying BOT and BAL. Scaling up the CDMO business will take at least 2-3 years. We're optimistic about the clinical and regulatory progress of BOT and BAL, and anticipate meaningful Bio CDMO revenue over that timeframe."

Question 2: "If I were to look at FY27, what should be a good cost estimate? I think we're close to about Rs.1,600-Rs.1,650 crores. What would be this number on a run rate basis in FY27?"

Answer: "Our current run rate for other expenses, excluding R&D, is expected to be around Rs.1,750-Rs.1,800 crores. But this does not include costs from Agenus and Saro, which will be added later. We will provide more accurate guidance after finalizing the budget, likely in Q4."

Question 3: "The R&D cost has gone up significantly this quarter. What is going to drive this further increase?"

Answer: "We expect our R&D to be around 7.5%-8% of revenue for FY26. The increase in this quarter is typical due to lumpy expenses from various clinical trials, particularly in biologics. This quarter often has higher R&D spending, as noted in previous years."

Question 4: "What are the key triggers for US growth over the next two years, especially regarding specialty opportunities?"

Answer: "We're planning 40-45 product launches in FY27 and have significant specialty launches, including our pipeline for 505(b)(2) products. Our generics business has seen robust volume growth of 11%, and we expect this momentum to continue alongside new specialty drugs entering the market."

Question 5: "What are the growth expectations for the vaccine business over the next few years?"

Answer: "We project significant growth expectations for our vaccine portfolio, aiming for a thousand crore business through various public tenders and strong traction in products like rabies and flu vaccines. The growth path is set for the next 3-4 years."

Question 6: "Could you provide an update on your M&A strategy for scaling up US Specialty business?"

Answer: "We're focusing on specialty-driven opportunities and hope to complete at least one acquisition annually. Alongside the successful launch of Zycubo, we're keen on expanding our 505(b)(2) specialty space and continue to seek relevant commercial assets in areas like liver diseases."

Question 7: "What is the timeline for the GLP-1 launches in India, and will Zydus be in the first wave of launches?"

Answer: "We will definitely be in the first wave of GLP-1 launches in India, backed by our novel formulation that offers easier usability for patients and potential cost benefits. We're also partnering with multiple firms to accelerate the launch."

Question 8: "What are the key levers for the expected increase in operating expenses excluding R&D?"

Answer: "The higher operating expenses are largely due to recent acquisitions. We're not adding field forces for current acquisitions, though future launches like Saro will necessitate a dedicated commercial team, which isn't accounted for in current estimates."

This summary captures the discussion from the Q&A session, conveying the key questions and answers succinctly.